Tekmira Gets Fast Track Designation From FDA For TKM-Ebola

(RTTNews) - Tekmira Pharmaceuticals Corp. (TKMR, TKM.TO) said Wednesday that the U.S. Food and Drug Administration has granted Fast Track designation for the development of TKM-Ebola, an anti-Ebola viral therapeutic.

The FDA's Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions.

Tekmira's anti-viral product platform includes RNAi therapeutics addressing chronic Hepatitis B infection and lethal hemorrhagic fever viruses, including Ebola and Marburg.